John Huang

John Huang

McDermott Will & Emery

Contact  |  View Bio  |  RSS

Latest Publications

Share:

China's Latest Enforcement of the Anti-Monopoly Law and Price Supervision/Regulation

China's National Development and Reform Commission (NDRC) recently outlined its latest efforts in the enforcement of the Anti-Monopoly Law and price supervision. This newsletter summarizes the noteworthy information NDRC...more

2/26/2014 - Anti-Monopoly Automotive Industry China Instant Milk NDRC Qualcomm Telecommunications

China Solicits Comments on Good Supply Practices for Medical Devices

The China Food and Drug Administration recently published a draft regulation setting minimum standards for medical device distribution. The regulation sets forth requirements for procurement, delivery acceptance, storage,...more

2/19/2014 - CFDA China Medical Devices Supply Chain

Whistleblowing in China and the United States

The Chinese Government’s wide-ranging bribery and corruption investigation into the pharmaceutical industry takes a new turn every week. Media reports contain numerous incidents of purported whistleblowers making allegations...more

8/30/2013 - Bribery China Compliance Corruption Dodd-Frank False Claims Act Pharmaceutical Risk Management Whistleblower Awards Whistleblowers

Ministry of Human Resources and Social Security Seeks Comments on Regulating Labor Dispatch

China’s Ministry of Human Resources and Social Security issued provisions that align closely with recent changes to the PRC Labor Contract Law in order to help standardize labor dispatch in the country. The draft calls for a...more

8/16/2013 - China Employment Contract Grace Period Proposed Legislation Social Security

Observations on a Milestone Bribery Investigation and Increased Scrutiny of Foreign Companies in China

The Chinese government’s recent crackdown on alleged bribery and corruption of local officials by multinational pharmaceutical companies could signal a broad trend toward elevated scrutiny of all foreign corporations...more

7/30/2013 - Bribery China Compliance Corruption Due Diligence FCPA Foreign Corporations GlaxoSmithKline UK Bribery Act

Distribution in China – Legal Issues

McDermott Will & Emery is pleased to offer “Distribution in China – Legal Issues*,” a one-stop resource covering distribution in China, including: The business models and legal structures most commonly used for...more

4/4/2013 - Bribery Business Taxes China Commercial Agents Compliance Contract Drafting Covenant of Good Faith and Fair Dealing Customs Distributors E-Commerce Exports FCPA Foreign Investment Franchises Imports Joint Venture Price-Fixing Private Equity Retailers Trademarks UK Bribery Act Unfair Competition Wholesale

Distribution in China – Legal Issues Part IV. Drafting the Distribution Contract

“Distribution in China – Legal Issues” is a four-part series. Part I discussed the business models and legal structures most commonly used for distribution in China. Part II looked at important issues to consider in the...more

3/21/2013 - China Confidentiality Agreements Contract of Adhesion FCPA Letters of Intent Memorandum of Understanding Termination UK Bribery Act

Distribution in China – Legal Issues Part III. Pre-Contract Matters

McDermott Will & Emery has a strategic alliance with MWE China Law Offices, a separate law firm based in Shanghai. "Distribution in China – Legal Issues” is a four-part series. Part I discussed the business models...more

3/7/2013 - China Corruption Distributors FCPA UK Bribery Act

8 Results
|
View per page
Page: of 1